Velaglucerase alfa

Specification

• Cat#: THP-0099
• Product Name: Velaglucerase alfa
• Description: The product is a gene-activated human recombinant glucocerebrosidase.
• Sequences: ARPCIPKSFGYSSVVCVCNATYCDSFDPPTFPALGTFSRYESTRSGRRMELSMGPIQANHTGTGLLLTLQPEQKFQKVKGFGGAMTDAAALNILALSPPAQNLLLKSYFSEEGIGYNIIRVPMASCDFSIRTYTYADTPDDFQLHNFSLPEEDTKLKIPLIHRALQLAQRPVSLLASPWTSPTWLKTNGAVNGKGSLKGQPGDIYHQTWARYFVKFLDAYAEHKLQFWAVTAENEPSAGLLSGYPFQCLGFTPEHQRDFIARDLGPTLANSTHHNVRLLMLDDQRLLLPHWAKVVLTDPEAAKYVHGIAVHWYLDFLAPAKATLGETHRLFPNTMLFASEACVGSKFWEQSVRLGSWDRGMQYSHSIITNLLYHVVGWTDWNLALNPEGGPNWVRNFVDSPIIVDITKDTFYKQPMFYHLGHFSKFIPEGSQRVGLVASQKNDLDAVALMHPDGSAVVVVLNRSSKDVPLTIKDPAVGFLETISPGYSIHTYLWRRQ
• Species: Human
• Molecular Weight: 63000.0 Da (approximate)
• Purity: >99% by SDS-Page and HPLC analysis
• Cas No: 884604-91-5
• Formula: C2532H3850N672O711S16
• Endotoxin Level: <0.001 EU per 1 μg by the LAL method
• Biological Activity: 400U/2.5mg

Pharmaceutical Information

• Pharmaceutical Application: Velaglucerase alfa
• Applications: The product is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for long-term enzyme replacement therapy for pediatric and adult patients with type 1 Gaucher disease.
• Examples of Clinical Use: Type 1 Gaucher disease
• Pharmacodynamics: Not Available
• Mechanism of action: Velaglucerase alfa catalyzes the hydrolysis of glucocerebroside, reducing the amount of accumulated glucocerebroside.
• Affected organisms: Not Available
• Targets: Target 1. Glucosylceramidase